Neogen Corporation (NEOG)

Currency in USD
11.29
-0.11(-0.96%)
Closed·
11.300.00(0.00%)
·
NEOG is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
11.1511.62
52 wk Range
4.7812.85
Key Statistics
Prev. Close
11.4
Open
11.45
Day's Range
11.15-11.62
52 wk Range
4.78-12.85
Volume
1.76M
Average Volume (3m)
2.35M
1-Year Change
136.6876%
Book Value / Share
9.61
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NEOG Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
13.00
Upside
+15.15%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Neogen Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy

Analyst Ratings

2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 13.00
(+15.15% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Piper Sandler
Hold13.00+15.15%11.00MaintainAug 03, 2026
William Blair
Hold---MaintainApr 09, 2026
William Blair
Hold---MaintainMar 02, 2026
Piper Sandler
Hold10.00-11.43%6.50MaintainJan 12, 2026
William Blair
Hold---MaintainJan 09, 2026

Neogen Corporation Earnings Call Summary for Q4/2026

  • Neogen Q4 revenue hit $225.3M, beating estimates by 6%; adjusted EPS of $0.09 topped forecasts by 80%, driving shares up 10.4% premarket to $10.38.
  • Food safety sales rose 5.8% on core basis, strongest growth since 2023; adjusted EBITDA climbed 12% YoY to $45.4M with margin expansion of 330bps.
  • FY2027 guidance: revenue of $880-885M with 3% core growth; adjusted EBITDA of $180-182M, implying 20.5% margin at midpoint despite heavy investments.
  • Company plans 50% R&D spending increase in FY2027, targeting 5% of revenue long-term; new Petrifilm line expected to add 200-300bps gross margin by FY2028.
  • Management signals shift from stabilization to growth phase; $794M debt remains after $20M repayment; Genomics divestiture awaits regulatory approval.
Last Updated: 2026/07/30, 15:04
Read Full Transcript

Earnings

Latest Release
Jul 30, 2026
EPS / Forecast
0,09 / 0,05
Revenue / Forecast
225,3M / 212,52M
EPS Revisions
Last 90 days

NEOG Income Statement

Compare NEOG to Peers and Sector

Metrics to compare
NEOG
Peers
Sector
Relationship
P/E Ratio
−314.4x−8.9x−0.4x
PEG Ratio
−3.17−0.240.00
Price/Book
1.2x2.9x2.6x
Price / LTM Sales
2.9x2.7x3.0x
Upside (Analyst Target)
15.1%12.1%51.8%
Fair Value Upside
Unlock−7.0%7.2%Unlock

Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns for food producers and processors. It also provides reagents and test kits used in immunoassay production, forensic and animal toxicology, and life science research; unique colorimetric and chemiluminescent substrates for research use; veterinary instruments and delivery systems used for administering antibiotics and vaccines under the Ideal and Prima Tech brands; and precision instruments designed for injections, topical and oral administration, artificial insemination, and animal identification for farmers, ranchers, and veterinarian under the Prima Tech brand. In addition, the company offers digestive aids and nutritional supplements; Natural Vitamin E-AD to address vitamin deficiencies in swine, cattle, and sheep; RenaKare; companion animal parasiticides under Provecta brand; BotVax B; EqStim; ImmunoRegulin, used in dogs to assist in managing pyoderma; companion animal parasiticides under the Provecta brand; rodent and insect control products under the Ramik, CyKill, Havoc, Prozap, SureKill, and StandGuard brands. Further, it markets Uniprim, a veterinary antibiotic; operates sgenomics labs offering DNA genotyping, sequencing, and trait analysis for livestock and companion animals; and provides software systems that help testers to analyze and store results and perform analysis on the results from multiple locations over extended periods. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
115,99M53,28%1,32B
Other Institutional Investors
130,41M46,72%1,49B
Public Companies & Retail Investors
0,000,00%0,00
Total
246,4M100,00%2,81B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.14,99%32 621 005371 879
Neuberger Berman Investment Advisers LLC7,40%16 109 771183 651

FAQ

What Is the Neogen (NEOG) Stock Price Today?

The Neogen stock price today is 11,29 USD.

What Stock Exchange Does Neogen Trade On?

Neogen is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Neogen?

The stock symbol for Neogen is "NEOG."

What Is the Neogen Market Cap?

As of today, Neogen market cap is 2,49B USD.

What Is Neogen's Earnings Per Share (TTM)?

The Neogen EPS (TTM) is -0,04.

When Is the Next Neogen Earnings Date?

Neogen will release its next earnings report on Oct 08, 2026.

From a Technical Analysis Perspective, Is NEOG a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Neogen Stock Split?

Neogen has split 6 times.

How Many Employees Does Neogen Have?

Neogen has 2636 employees.

What is the current trading status of Neogen (NEOG)?

As of Aug 06, 2026, Neogen (NEOG) is trading at a price of 11,29 USD, with a previous close of 11,40 USD. The stock has fluctuated within a day range of 11,15 USD to 11,62 USD, while its 52-week range spans from 4,78 USD to 12,85 USD.

What Is Neogen (NEOG) Price Target According to Analysts?

The average 12-month price target for Neogen is 13,00 USD, with a high estimate of 14 USD and a low estimate of 12 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +15,15% Upside potential.

What Is the NEOG Premarket Price?

NEOG's last pre-market stock price is 11,30 USD. The pre-market share volume is 5 800,00, and the stock has decreased by -0,10, or -0,88%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.